TITLE

Nothing Sacred

AUTHOR(S)
Mulholland, Stephen
PUB. DATE
April 2011
SOURCE
Finweek;4/28/2011, p21
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
In this article the author highlights the underlying factors that add to the cost of production and the total cost of a marketable branded drug manufactured by pharmaceutical companies like research and development, shareholders interests in the form of dividends. For an average hypochondriac in his quest for cheap prescriptions, the author suggests concoctions from generic producers offering drugs similar to the patented products of big companies and a referral to the website Health24.com.
ACCESSION #
61097480

 

Related Articles

  • International Prices And Availability Of Pharmaceuticals In 2005. Danzon, Patricia M.; Furukawa, Michael F. // Health Affairs;Jan/Feb2008, Vol. 27 Issue 1, p221 

    This paper compares pharmaceutical spending, availability, use, and prices in twelve countries in 2005. Drug spending per capita was higher in the United States than in other countries. The United States had relatively high use of new drugs and high-strength formulations; other countries used...

  • Betting on biogenerics. Dove, Alan // Nature Biotechnology;Feb2001, Vol. 19 Issue 2, p117 

    Focuses on the decision taken by the pharmaceutical industry to manufacture own versions of generic drugs. Reason for the industry's decision; Scope of the drug manufacturing business in the global market; Steps to be taken by manufacturers to produce generic drugs similar to branded drugs;...

  • FILLING THE PHARMA PIPELINE.  // Chemistry in Australia;Dec2011, Vol. 78 Issue 11, p9 

    The article reveals that a number of blockbuster patents will expire and generic pharmaceuticals will win market share from the originator pharmaceutical companies in Australia in 2012.

  • Generics. Marsh, Peter // BMJ: British Medical Journal (International Edition);12/2/89, Vol. 299 Issue 6712, p1357 

    Focuses on the dispute in the drug industry between the research based pharmaceutical companies and smaller groups for product patents. Action of the research groups for generic prescription; Argument of the research groups over the government policy; Explanation of the factors of anguish to...

  • Patent Losses To Create Big Opportunities.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p65 

    The article presents the EvaluatePharma report which highlights the challenges that confront the innovator drug industry and the opportunities awaiting the generics drug sector, and shows that 13 blockbuster drugs will lose patent protection in 2013 in the U.S.

  • Branded drug companies' future pain spells big gains for generic drug makers. West, Diane // Drug Store News;03/04/2002, Vol. 24 Issue 3, p28 

    Reports on the business opportunity of generic drug makers from brand name prescription drugs' patent protection loss by 2005, according to the report, 'The Generics Industry in 2005: A New Threat to Pharma.' One tactic of generic makers to stay on top; Cost of going after high-ticket drugs;...

  • Patents hold no guarantee in new generics marketplace. Kirsche, Michelle L. // Drug Store News;11/17/2003, Vol. 25 Issue 16, p26 

    Reports that patents hold no guarantee as generic drugs take a larger share of the pharmaceutical industry. Major branded drugs that lost patent protection in 2002; List of top 10 generics companies by prescription; Advantages of early patent legal challenges; Campaign to reduce regulatory...

  • Pharma patent settlements in EU continue to rise.  // PharmacoEconomics & Outcomes News;Dec2013, Issue 693, p10 

    The article reports on the findings of a survey by the European Commission which shows an increase in the number of patent settlement agreements between originator and generic companies in 2012 which has reached 1883, up 120 in 2011.

  • Generic Medicines and Patenting of Medicinal Biotechnology in India: An Assessment of Political and Economic Stakes. Srivastava, S. P. // Effective Executive;Sep2012, Vol. 15 Issue 3, p36 

    In the pharmaceutical industry, firms normally invest hundreds of millions of dollars in R&D and clinical trials on their drugs before they are sold in the market, while their generic medicine rivals are exempted from those requirements and enter the market at low cost with nominal investments....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics